MIG Capital

🫀 Building a successful MedTech company is a long game. So why do VCs still find it attractive? Cardiovascular disease remains the leading cause of death in Europe, while Europe itself has become an important hub for new interventional cardiology technologies. As our graphic shows, getting a MedTech company from idea to exit takes quite a few steps. So why is the space still so interesting for VC investors? 🔬 The medical need is clear. Many cardiovascular conditions still require highly invasive procedures or have limited treatment options. 📈 New technologies can change the standard of care. TAVI is a strong example: what started as an experimental procedure has become an established treatment for aortic valve disease. 🛡️ The barriers to entry are high. Europe combines strong engineering expertise with highly specialized MedTech companies. 🤝 There is an established market of strategic buyers. Major MedTech companies actively acquire innovative startups and bring their technologies to market. We see this development in our own portfolio with CoreMedic, which is developing a catheter-based system for mitral valve repair, one example of the broader shift toward minimally invasive treatment of heart disease. ➡️ In an article for GoingPublic Media AG, our Venture Partner Matthias Guth looks at why Europe is becoming such an important hub for the next wave of interventional cardiology, where he sees the biggest opportunities and why the space remains attractive for investors. Read the full article via the link in the comments below. (AI generated image)

🇨🇳 China is becoming a serious force in global Biotech. But why should European Life Science startups care? Over the past 20 years, China has moved from being seen mainly as a manufacturing base and commercial market to becoming a serious source of innovation. Since 2023, a wave of major licensing deals has made that shift especially visible. We are seeing strong activity in areas like ADCs, bispecific antibodies and oncology, with more Chinese assets reaching Phase II and attracting interest from global pharma. For European startups, this is changing both the competitive landscape and the opportunity set. A few things stand out to us: 🌍 Competition is global. The closest competing asset might just as well come from Shanghai as from Boston. ⚡ Speed matters. But only together with strong science, robust clinical data and a global development strategy. 🤝 China is not just competition. It is also becoming an important source of assets, technologies, clinical development opportunities and partnerships. One of the key messages from our colleague Dr. Fei Tian's three-part interview with GoingPublic Media AG: the best asset doesn’t have a passport. 👇 Link to the interview in the comments. (AI generated image)

From seed stage to ringing the Nasdaq Closing Bell. 🔔🗽 Last week, IQM Quantum Computers celebrated its recent public listing by ringing the Closing Bell at Nasdaq in New York. A special moment for European deep tech, and an especially special one for us at MIG Capital. We were among IQM Quantum Computers’ founding investors and have backed the company through several MIG Fonds over many years. And our connection goes beyond capital: Dr. Soren Hein, today IQM’s Deputy CEO and COO, was once part of the MIG team himself. ➡️ That makes this milestone particularly meaningful for us. It is a great example of what long-term venture capital can look like: identifying ambitious technology early, backing the right people and staying close to the journey as a company grows from its early days to the public markets. Congratulations to the entire IQM team. We are proud to have been part of this journey and excited to see what comes next. 🎉 Watch the bell ringing via the link in the comments below. Jan Goetz Sylwia Barthel de Weydenthal Dimitrios P. Jan Kuerschner Juha Vartiainen Craig Ciesla Inés De Vega Christina Vogt-Sasse Frederick Michna

📣Portfolio News: NavVis raises $85M to fuel physical AI in industry and construction Our MIG Fonds portfolio company NavVis has raised $85 million in a Series D round, led by TJC, alongside existing shareholders Yttrium, Kozo Keikaku Engineering, Inc. and Cipio Partners. The funding will: 🤖 advance the AI layer that makes spatial data semantic, actionable and accessible ⚙️ invest in next-generation technology and infrastructure to scale spatial data 🏗️ make this data accessible to millions of operators, as well as robots and AI agents across #Construction and #Industry For us as investors, a round of this size is a strong signal of the confidence in NavVis, its technology and the market opportunity ahead. Huge congrats to the whole NavVis team! 🚀 Read the full press release in the comments ⬇️ Felix Reinshagen Georg Schroth Finn Boysen Stephan Kniewasser Frederick Michna Kristian Schmidt-Garve

Standing on the shoulders of giants: We had the honor of ringing the Nasdaq Closing Bell yesterday! You can watch the Bell ringing recording here: https://lnkd.in/eCcTDbBP A moment of joy, pride, and humbleness given the long list of epic companies that did this step before us over the last 55 years. I can only thank our great team, all our supporters, partners, customers, and shareholders who trusted in us over the years and made this step possible! Getting to this point means overcoming challenges that were thought to be impossible. Hundred years ago, some scientists were still questioning quantum theory as such. Twenty years ago, some technologists were still questioning whether a quantum computer could be built. Today, some people are still questioning the commercial usefulness of quantum computers. With IQM Quantum Computers, we prove that there is a solution to all of these questions by solving the hard problems on a daily basis. We show that the technology works today, that there is a roadmap to commercial success, and that the business model can be scaled. A concept we call Production Quantum. After holding our first earnings call earlier this week, I am looking forward to many more quarters to come! Blair Robertson Chiara Mantegani Jan Kuerschner Henrik Klobut Mark Falcon Juha Vartiainen Sylwia Barthel de Weydenthal Soren Hein Craig Ciesla Inés De Vega Dimitrios P. Tomi Riipinen Juha Hassel Pasi Kivinen

European quantum computing meets the most German use case imaginable: Deutsche Bahn. 🚆 Our MIG Fonds portfolio company IQM Quantum Computers collaborated with Deutsche Bahn on a research project exploring how quantum computing could improve railway scheduling. Here is what they found: 💪🏽 The approach works on today’s hardware. 📈 It can improve as quantum processors become more powerful. 🤩 The full process ran end to end on IQM hardware and produced feasible schedules. ➡️ Quantum computing is often discussed as a promising future technology, but this project demonstrates a clear and practical use case that already works on today’s hardware. It also reflects IQM’s focus on bringing quantum computing into enterprises through systems that customers can own, operate and continue building on. Read more in IQM's press release and the white paper. Link in the comments. Jan Goetz Soren Hein Christina Vogt-Sasse Frederick Michna

A life science problem tackled from the tech side? Name a better fit for our MIG Fonds portfolio! 🧫 Christina Vogt-Sasse and Johannes B. Woehrstein about mbiomics GmbH ⬇️

🧵 Bioengineered Silk, Scaled in Europe. Our MIG Fonds portfolio company AMSilk | Biogenius Materials expands its partnership with Ajinomoto Foods Europe, Solutions & Ingredients to enable the industrial-scale production of AMSilk’s silk proteins. Here's what you need to know: 🏭 Under a long-term manufacturing and supply agreement, Ajinomoto Foods Europe will establish a dedicated production line for AMSilk at its site in Nesle, France. 🤝 This agreement combines AMSilk’s proprietary biotechnological process with Ajinomoto Foods Europe’s expertise in precision fermentation and biomanufacturing. Supported by a joint multi-million investment, it marks the transition from industrial validation to dedicated large-scale production. Why does it matter? 🇪🇺 The partnership strengthens production capacity, supply security and operational resilience in Europe, while supporting locally sourced raw materials and renewable energy. 📈 For investors following #IndustrialBiotechnology and #SustainableMaterials, it demonstrates how biotechnology and established manufacturing expertise can come together to advance industrialisation at scale. Read AMSilk's press release in the link in the comments ⬇️ Dr. Nicolas Rose-André Christian Wichert Gudrun Vogtentanz Ulrich Scherbel Ctibor Kohutovič Jeno Schadrack